Injectable Oncology Medical Program Update
Effective October 1, 2022, Herceptin Hylecta and Rituxan Hycela products will now be added to Blue Cross and Blue Shield of North Carolina’s (Blue Cross NC) ’s Preferred Injectable Oncology Program policy as non-preferred products.
These products will no longer require submission through the AIM Provider Portal in Blue e. Requests for these products for an applicable commercial member will need to be submitted through CoverMyMeds instead of through the AIM portal starting 10/1/2022.
AIM will continue to conduct clinical reviews for all other drugs in the AIM medical oncology program.
For more information, please refer to the medical policy (PDF) or refer to Getting Your Patient's Prescriptions Covered.
What you should know
- This change applies to all commercial members with the AIM oncology program through Blue Cross NC.
- This follows a similar process to how our other medical drugs are reviewed at Blue Cross NC.
- We do not anticipate any member disruption.
Blue Cross and Blue Shield of North Carolina does not discriminate on the basis of race, color, national origin, sex, age or disability in its health programs and activities. Learn more about our non-discrimination policy and no-cost services available to you.
Information in other languages: Español 中文 Tiếng Việt 한국어 Français العَرَبِيَّة Hmoob ру́сский Tagalog ગુજરાતી ភាសាខ្មែរ Deutsch हिन्दी ລາວ 日本語
© 2024 Blue Cross and Blue Shield of North Carolina. ®, SM Marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield plans. All other marks and names are property of their respective owners. Blue Cross and Blue Shield of North Carolina is an independent licensee of the Blue Cross and Blue Shield Association.